1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cenntro Inc. closed a private placement on September 15, 2026, after amending its August 25, 2026 purchase agreement on September 14 to raise the offering size. The company received gross proceeds of approximately $57,047,760 and says it will use the money for working capital and general corporate purposes. Shareholders face dilution from the sale of up to 15,120,000 new shares at $3.773 each.
Sale of up to 15,120,000 shares of common stock at $3.773 per share, up from an original offering of up to 12,800,000 shares
Gross proceeds of approximately $57,047,760; private placement closed September 15, 2026
Shares sold to non-U.S. accredited investors under Section 4(a)(2) and Regulation S, without general solicitation
Proceeds intended for working capital and general corporate purposes
Beta Bionics priced an underwritten public offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares, with gross proceeds expected to be about $150.0 million before underwriting discounts and expenses. The company expects to use the net proceeds for general corporate purposes, including costs of commercializing Mint and manufacturing expansion, and the offering is expected to close on September 17, 2026. The sale of new shares will increase the number of shares outstanding, which affects existing shareholders' ownership.
Offering of 7,652,175 common shares at $17.25 per share, plus pre-funded warrants for 1,043,484 shares at $17.2499 per share
Gross proceeds expected to be about $150.0 million before underwriting discounts and offering expenses
Underwriters have a 30-day option to buy up to 1,304,348 additional shares at the public offering price
Expected closing on September 17, 2026; J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are the underwriters
Nordicus Partners issued a $600,000 convertible grid promissory note to Keystone Capital Partners on September 10, 2026, in exchange for $500,000 in cash. The company also agreed to issue the lender 250,000 shares of common stock as consideration for the funding commitment. Conversion into common stock is possible only after an Event of Default and from June 10, 2027, at 90% of VWAP, so existing shareholders could face dilution.
Principal of $600,000 for $500,000 in cash; interest at 5.0% per annum; matures June 10, 2027
Company agreed to issue 250,000 Commitment Shares to the lender
Conversion only after an Event of Default and from June 10, 2027, at 90% of the 10-day VWAP
Company must file a resale registration statement on or before November 1, 2026
Tenon Medical said holders exercised 572,179 existing warrants at $5.02 per share, bringing gross proceeds of $2,872,338.58, and received new five-year warrants for 858,269 shares at the same price. The deal was announced September 11, 2026 and closed September 14, 2026, with the company stating it will use the proceeds for working capital and general corporate purposes. Shareholders may face dilution if the new warrants are exercised, and the company agreed to register the resale of the underlying shares.
Existing warrants for 572,179 shares were exercised at $5.02 per share, with gross proceeds of $2,872,338.58, according to the filing.
New Series B warrants cover up to 858,269 shares, equal to 150% of the shares issued on exercise, with a $5.02 exercise price and a five-year term.
WallachBeth Capital LLC, the financial advisor, will receive a cash fee of 7% of gross proceeds plus legal expense reimbursement up to $65,000.
Tenon must file a resale registration statement within 30 calendar days of September 11, 2026 and seek effectiveness within 60 days, or 90 days if the SEC conducts a full review.
On September 14, 2026, Essential Properties Realty Trust and its operating partnership signed an eighth amendment to their Amended and Restated Credit Agreement with Wells Fargo as administrative agent. The amendment raises revolving commitments from $1.0 billion to $1.3 billion, lowers margin pricing, and resets the accordion feature, and the company repaid and terminated its Capital One credit agreement in connection with it. The filing does not give a financial impact beyond these terms.
Revolving Credit Facility commitments increase from $1.0 billion to $1.3 billion, per the amendment dated September 14, 2026.
Margin grid pricing for the Revolving Credit Facility and term loans is reduced.
Accordion feature reset to permit $700.0 million of availability.
Obligations under the Capital One Credit Agreement were repaid in full and that agreement was terminated; Subsidiary Guarantors were released from their guarantee obligations.
On September 11, 2026, ProFrac and the parties to its Alpine term loan signed Amendment No. 5, which cuts required quarterly principal payments to $0 through March 31, 2028 and extends maturity to February 15, 2030. The same day, $60 million of term loans was assigned to THRC Holdings and Farris C. Wilks, a co-founder and principal stockholder, and was repaid through the transfer of 2,306,806 Flotek shares owned by a ProFrac subsidiary, which gives the company near-term repayment relief but also a related-party transaction and tighter cash-flow and distribution terms.
Quarterly amortization reduced from $15 million to $0 for quarters ending September 30, 2026 through March 31, 2028, then $10 million per quarter.
Maturity extended from January 26, 2029 to February 15, 2030; PFP Holding may pay 675 basis points of interest in kind for 12 months from September 1, 2026.
$60 million of 2026 Term Loans assigned to THRC Holdings ($34.32 million) and Farris C. Wilks ($25.68 million) and cancelled in exchange for 2,306,806 Flotek shares.
Borrower must prepay 100% of excess cash flow each quarter, and company distributions are restricted to a $1 million annual basket.
Public Storage's subsidiary PS Canada Finance ULC completed a C$400 million offering of 4.540% senior notes maturing September 16, 2033, guaranteed by Public Storage and its subsidiary PSOC. The filing describes a standard debt issuance with covenants limiting mergers and requiring PSOC to keep unencumbered assets at or above 125% of unsecured debt.
Notes: C$400 million, 4.540% fixed interest, payable semi-annually from March 16, 2027
Maturity: September 16, 2033; redeemable at make-whole price, or at 100% of principal plus accrued interest from July 16, 2033
Covenant: PSOC must maintain unencumbered assets of at least 125% of total unsecured indebtedness
On September 10, 2026, Empire Petroleum Corporation issued a $3,250,000 promissory note to Petroleum Independent & Exploration, LLC, which has fully advanced the funds for general working capital. The note matures March 10, 2028 and carries 6% annual interest, and PIE may convert principal into common stock at $2.838 per share from November 9, 2026, which would issue 1,145,173 shares if fully converted. The filing adds debt and could dilute existing shareholders if converted, and it contains no revenue, profit or guidance figures.
$3,250,000 note issued September 10, 2026 to PIE; full amount advanced as of that date
6% annual interest, rising to 9% on any principal unpaid after the March 10, 2028 maturity; accrued interest payable in cash at maturity
Convertible at PIE's option from November 9, 2026 to maturity at $2.838 per share, for up to 1,145,173 shares
Prepayable without penalty on at least five business days' written notice; company will seek NYSE American approval for the underlying shares
On September 16, 2026, Teva's subsidiaries issued €1.5 billion and $3.2 billion of senior unsecured notes due 2032 to 2037, guaranteed by Teva Pharmaceutical Industries. Teva plans to use the proceeds to fund conditional redemptions of several existing notes, pay related fees, and for general corporate purposes. The filing shows a refinancing of existing debt rather than a stated change in operations or results.
Euro notes: €1.0 billion of 4.250% notes due March 16, 2033, and €500 million of 4.625% notes due September 16, 2036
USD notes: $1.2 billion of 5.250% notes due January 16, 2032; $1.0 billion of 5.500% notes due January 16, 2034; and $1.0 billion of 5.750% notes due January 16, 2037
Conditional redemptions include up to $450 million of 4.750% notes due 2027 and up to €1.15 billion of 4.375% notes due 2030, reduced from up to €1.25 billion
Teva may redeem notes, or issue further redemption notices, at its sole discretion and is under no obligation to do so
Martin Marietta and its subsidiary Martin Marietta Funding LLC signed an amendment on September 15, 2026, extending the maturity of their $500 million trade receivables securitization facility to September 15, 2027. The facility can be increased to up to $700 million if lenders provide the required commitments, and borrowings now bear interest at Adjusted Term SOFR plus 0.700%.
Maturity extended to September 15, 2027 under the Eighteenth Amendment with Truist Bank as administrative agent
Facility size is $500 million, with a possible increase to up to $700 million subject to conditions
Borrowings bear interest at Adjusted Term SOFR plus 0.700%, subject to change if SOFR benchmarks cannot be determined or no longer reflect lenders' cost of lending
Oaktree Specialty Lending Corporation issued $300.0 million of 7.000% unsecured notes maturing September 16, 2031, and the transaction closed the same day. The company expects to use the net proceeds to reduce borrowings under its senior secured revolving credit facility and for general corporate purposes, which may include repaying 2.700% notes due 2027 at maturity.
Notes: $300.0 million aggregate principal, 7.000% annual interest, paid semiannually on March 16 and September 16 starting March 16, 2027
Maturity September 16, 2031; callable at a make-whole price (Treasury Rate plus 40 basis points) before August 16, 2031, and at par thereafter
Holders may require repurchase at 100% of principal plus accrued interest upon a Change of Control Repurchase Event
Offering made under shelf registration No. 333-292920; transaction closed September 16, 2026
On September 15, 2026, My Size agreed to sell up to 1,308,901 shares of common stock, or pre-funded warrants in their place, at $1.91 each, along with Series C and Series D warrants, in a private placement expected to bring in about $2.5 million in gross proceeds before fees. The warrants are exercisable at $1.66 per share, so the deal would add up to roughly 2.6 million potential shares to the share count, which dilutes existing shareholders, and the company says the proceeds will go to general corporate purposes, including working capital.
Up to 1,308,901 shares or pre-funded warrants at $1.91 each; gross proceeds of about $2.5 million before placement agent fees and expenses
Series C and Series D warrants, each for up to 1,308,901 shares, exercisable immediately at $1.66 per share; Series C term is five years and Series D term is 18 months from the resale registration effective date
H.C. Wainwright & Co. is exclusive placement agent, with a 7% cash placement fee, a 1.0% management fee and placement agent warrants for 91,623 shares at $2.3875
Offering expected to close on or about September 16, 2026; company must file a resale registration statement within 15 days of signing and is barred from variable rate transactions for one year after the effective date
On September 11, 2026, USBC drew an additional $3.0 million under its Master Loan Agreement with Payward Interactive, bringing total principal outstanding to $21.0 million at a fixed 8.5% annual rate, maturing September 11, 2027. The loan is secured solely by 479 Bitcoin held by an affiliate custodian, and the filing says a roughly 27.4% drop in that collateral's value would have pushed the collateral coverage ratio to the 130% collateral call margin as of September 14, 2026, though no collateral calls, mandatory repayments or liquidations had occurred.
Fifth draw of $3.0 million on September 11, 2026; total outstanding rises to $21.0 million under the $25.0 million facility
Fixed interest rate of 8.5% per annum, with maturity on September 11, 2027 unless terminated earlier
479 Bitcoin collateral; a roughly 27.4% decline would have reached the 130% collateral call margin as of September 14, 2026
No collateral calls, mandatory repayments or liquidation events had occurred as of September 14, 2026
Schneider National Leasing, a wholly-owned subsidiary, entered a $350 million credit agreement on September 10, 2026, and terminated its existing $250 million credit agreement from November 2022, which had no outstanding borrowings. The company also amended its unsecured term loan agreement to conform its covenants to the new facility.
New $350 million credit facility matures September 10, 2031, with a Nov. 22, 2029 maturity if the term loan is not extended or refinanced in time
Borrower can request a commitment increase of up to $350 million, for a total potential commitment of $700 million
Existing $250 million credit agreement terminated effective September 10, 2026, with no outstanding borrowings
Term loan agreement, maturing November 22, 2029, amended to align covenants with the new facility
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.